About the Trulicity (dulaglutide) shortage

The current Trulicity (dulaglutide) supply situation

Eli Lilly has informed us that the shortage of Trulicity (dulaglutide) has now resolved.

The TGA has published updates about the supply of Trulicity from Eli Lilly on the Medicine Shortage Reports Database

Background

The worldwide shortage of Trulicity (dulaglutide) was closely related to the shortage of another diabetes medicine, Ozempic (semaglutide).

In June 2022, Eli Lilly told us there was a shortage of Trulicity due to an unexpected increase in demand. This increase in demand was closely related to the shortage of Ozempic, another diabetes medicine made by a different company. This is because some patients using Ozempic to treat their diabetes were moved to alternate medicines, including Trulicity. In early 2025, Eli Lilly informed us that the shortage of Trulicity has also been impacted by manufacturing issues. 

Throughout the shortages, we have received hundreds of messages with comments and questions from people who have been affected, many with similar concerns. We recognise the importance of Trulicity for patients living with diabetes, and we have taken these shortages very seriously. 

Our role in medicine shortages is to reduce the impact on patients where possible. In the Trulicity shortage, we:

• approved suitable overseas medicines for temporary use during the shortage
• met with the other pharmaceutical company, medical colleges and health professional organisations about how to get Ozempic to the people who need it most, to take the pressure off the supply of Trulicity
• liaised closely with Eli Lilly and communicating updates on the Medicine Shortage Reports Database

You can read more about how we manage medicine shortages in the information for consumers section of our website.

The Trulicity shortage has now resolved.

Facts about Trulicity

Trulicity is a brand of the medicine called dulaglutide. Trulicity:

• is supplied by pharmaceutical company Eli Lilly
• is a weekly injection
• is an antidiabetic medicine that is different to insulin
• is only approved by us for lowering blood sugar in adults with type 2 diabetes and to reduce the risk of major cardiovascular disease in adults with type 2 diabetes
• is subsidised on the Pharmaceutical Benefits Scheme (PBS) for treatment of type 2 diabetes when certain conditions are met.

You can read more about Trulicity in the Consumer Medicine Information (CMI).